NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Publication/Presentation Date

7-1-2019

Abstract

With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical consensus guideline for the administration of 177Lu-DOTATATE. In this paper, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment location and room preparation, drug administration, and patient release as well as strategies for radiation safety, toxicity monitoring, management of potential complications, and follow-up. Controversies regarding the role of radiation dosimetry are discussed as well. This document is designed to provide practical guidance on how to safely treat patients with this therapy.

Volume

60

Issue

7

First Page

937

Last Page

943

ISSN

1535-5667

Disciplines

Diagnosis | Gastroenterology | Hematology | Medicine and Health Sciences | Oncology | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Radiation Medicine | Radiology

PubMedID

31263080

Department(s)

Hematology-Medical Oncology Division, Department of Radiation Oncology, Department of Radiology and Diagnostic Medical Imaging

Document Type

Article

Link to Full Text

Share

COinS